A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer

Anti-Cancer Drugs

Volumn 23, Issue 5, 2012, Pages 543-552

  Musende, Alain Gulenga ^a,b   Eberding, Andy ^a   Wood, Catherine A ^a   Adomat, Hans ^a   Fazli, Ladan ^a   Hurtado Coll, Antonio ^a   Jia, William ^b,c   Bally, Marcel B ^b,d   Tomlinson Guns, Emma S ^a,b,d  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Faculty of Pharmaceutical Sciences   (United States)

Author keywords

biodistribution; efficacy; ginsenoside; pharmacokinetics; prostate cancer

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; GINSENOSIDE AGLYCONE PROTOPANAXADIOL; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TISSUE LEVEL; FEEDING; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE; STOMACH; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; DRUG STABILITY; GINSENOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS; SAPOGENINS; SOLID PHASE EXTRACTION; SOLUBILITY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859633021     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835006f5     Document Type: Article

References (36)

1. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary and alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000; 18:2505-2514. (Pubitemid 30432515)
2. 2+ channels through a pertussis toxin-sensitive G protein. Proc Natl Acad Sci USA 1995; 92:8739-8743.
3. Yun TK, Lee YS, Lee YH, Kim SI, Yun HY. Anticarcinogenic effect of Panax ginseng C.A. Meyer and identification of active compounds. J Korean Med Sci 2001; 16 (Suppl):S6-S18.
4. Zhang D, Yasuda T, Yu Y, Zheng P, Kawabata T, Ma Y, et al. Ginseng extract scavenges hydroxyl radical and protects unsaturated fatty acids from decomposition caused by iron-mediated lipid peroxidation. Free Radic Biol Med 1996; 20:145-150. (Pubitemid 26018506)
5. Duda RB, Zhong Y, Navas V, Li MZ, Toy BR, Alavarez JG. American ginseng and breast cancer therapeutic agents synergistically inhibit MCF-7 breast cancer cell growth. J Surg Oncol 1999; 72:230-239. (Pubitemid 30007793)
6. Kim HE, Oh JH, Lee SK, Oh YJ. Ginsenoside RH-2 induces apoptotic cell death in rat C6 glioma via a reactive oxygen- and caspase-dependent but Bcl-X(l)-independent pathway. Life Sci 1999; 65:PL33-PL40. (Pubitemid 29320416)
7. Fei XF, Wang BX, Tashiro S, Li TJ, Ma JS, Ikejima T. Apoptotic effects of ginsenoside Rh2 on human malignant melanoma A375-S2 cells. Acta Pharmacol Sin 2002; 23:315-322. (Pubitemid 34266588)
8. Oh M, Choi YH, Choi S, Chung H, Kim K, Kim SI, et al. Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol 1999; 14:869-875.
9. Park JA, Lee KY, Oh YJ, Kim KW, Lee SK. Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis. Cancer Lett 1997; 121:73-81. (Pubitemid 27504317)
10. Kim YS, Jin SH, Lee YH, Park JD, Kim SI. Differential expression of protein kinase C subtypes during ginsenoside Rh2-lnduced apoptosis in SK-N-BE(2) and C6Bu-1 cells. Arch Pharm Res 2000; 23:518-524.
11. Frei E. Principles of dose, schedule and combination chemotherapy. In: Kufe D, Holland J, Frei E, editors. Cancer medicine. 6: Hamilton, Ontario: BC Decker Inc.; 2003. pp. 669-677.
12. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
13. Budman DR, Calabro A, KreisW. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002; 13:1011-1016. (Pubitemid 36020671)
14. Xie X, Eberding A, Madera C, Fazli L, Jia W, Goldenberg L, et al. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models. J Urol 2006; 175:1926-1931.
15. Musende AG, Eberding A,Wood C, Adomat H, Fazli L, Hurtado-Coll A, et al. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemother Pharmacol 2009; 64:1085-1095.
16. Jin J, Shahi S, Kang HK, Hendrik WVV, Fan T. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 2006; 345:1308-1314. (Pubitemid 43817877)
17. Popovich DG, Kitts DD. Generation of ginsenosides Rg3 and Rh2 from North American ginseng. Phytochemistry 2004; 65:337-344. (Pubitemid 38147347)
18. Bae EA, Han MJ, Kim EJ, Kim DH. Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants. Arch Pharm Res 2004; 27:61-67.
19. Popovich DG, Kitts DD. Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line. Arch Biochem Biophys 2002; 406:1-8. (Pubitemid 35191710)
20. Wang W, Wang H, Rayburn ER, Zhao Y, Hill DL, Zhang R. 20(S)-25- methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer 2008; 98:792-802. (Pubitemid 351272613)
21. Liu GY, Bu X, Yan H, Jia WW. 20S-protopanaxadiol-induced programmed cell death in glioma cells through caspase-dependent and -independent pathways. J Nat Prod 2007; 70:259-264. (Pubitemid 46447640)
22. Yu Y, Zhou Q, Hang Y, Bu X, Jia W. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells. Cancer 2007; 109:2374-2382. (Pubitemid 46801570)
23. USP C. USP Pharmacopeia & National Formulary. Rockville, MD: Board of Trustees of the USP Pharmacopeial Convention, Inc.; 2000.
24. Sorby DL, Bitter RG,Webb JG. Dielectric constants of complex pharmaceutical solvent systems. I. Water-ethanol-glycerin and water-ethanol-propylene glycol. J Pharm Sci 1963; 52:1149-1153.
25. James KC. Solubility and related properties. New York: M. Dekker; 1986.
26. O'Neil MJ, Smith A, Heckelman PE, Obenchain JR, Gallipeau JAR, D'Arecca MA. The Merck Index. 13th ed. Whitehouse Station, NJ: Merck Research Laboratories; 2001.
27. Nagatomo I, Akasaki Y, HashiguchiW, Tominaga M, Uchida M, Takigawa MA. Solvent used for antiepileptic drugs increases serum and brain zonisamide concentrations in seizure-susceptible EL mice. Epilepsy Behav 2001; 2:357-362. (Pubitemid 33653394)
28. Lanigan RS. Final report on the safety assessment of PPG-11 and PPG-15 stearyl ethers. Int J Toxicol 2001; 20:53-59.
29. Xie HT, Wang GJ, Sun JG, Tucker I, Zhao XC, Xie YY, et al. High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 818:167-173. (Pubitemid 40331821)
30. Akao T, Kanaoka M, Kobashi K. Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration - measurement of compound K by enzyme immunoassay. Biol Pharm Bull 1998; 21:245-249. (Pubitemid 28166911)
31. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995; 16:351-380.
32. Xie HT, Wang GJ, Chen M, Jiang XL, Li H, Lu H, et al. Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco- 2 cells. Biol Pharm Bull 2005; 28:383-386. (Pubitemid 40880032)
33. Rapoport SI, Ohno K, Pettigrew KD. Drug entry into the brain. Brain Res 1979; 172:354-359. (Pubitemid 9232888)
34. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980; 23:682-684. (Pubitemid 11237830)
35. Chen SE, Sawchuk RJ, Staba EJ. American ginseng. III. Pharmacokinetics of ginsenosides in the rabbit. Eur J Drug Metab Pharmacokinet 1980; 5:161-168. (Pubitemid 11252888)
36. Wang W, Rayburn ER, Hao M, Zhao Y, Hill DL, Zhang R, et al. Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 2008; 68:803-918.